Valion Registers 3.95M-Share 3i Resale Overhang; Activist Now Holds 46% of Shares Outstanding
VBIO is trading near its 52-week low of $1.11 (1.8% above the low) on light trading volume (0.2× avg).
Summary
Valion Bio registered 3,954,381 shares for resale by its largest shareholder, 3i, LP, which now beneficially owns 46.17% of the company. The company gets no proceeds from the resale, and the filing quantifies the full conversion and warrant overhang for the first time.
Key Events · Financing and Capital Events · VBIO
-
3.95M Shares Registered for 3i Resale
Up to 3,954,381 shares of common stock registered for resale by 3i, LP, consisting of 536,159 shares from Series B conversion, 2,308,780 from Series C conversion, and 1,109,442 from warrant exercise.
-
3i Ownership Disclosed at 46.17%
3i beneficially owns 9,142,842 shares, or 46.17% of the 2,095,687 shares outstanding as of October 13, 2026, including 4,396,737 shares underlying a $15,916,188.81 senior secured note.
-
Conversion Prices Reset to $3.62
Series B and Series C conversion prices were adjusted to $3.62 per share on August 31, 2026, versus the $1.13 current stock price.
-
No Company Proceeds From Resale
Valion receives no proceeds from 3i's resale; only warrant exercises would bring cash, and the company has broad discretion over any such proceeds.
Analysis · VBIO · Life Sciences
This S-3 makes tradable the shares 3i, LP acquired through the Series B and Series C preferred financings and warrants — 3,954,381 shares, or roughly 1.9x the 2,095,687 shares outstanding as of October 13, 2026. The company receives no proceeds from the resale; only warrant exercises would bring in cash. The filing also reveals that 3i's total beneficial ownership is 9,142,842 shares, 46.17% of the company, including a $15.9M convertible note. Combined with the going-concern doubt reiterated in the August 10-Q and the $1.5M of new cash from the August 31 closing, the picture is a company dependent on a single activist investor whose stake is now largely registered for sale. The November 12 special meeting proxy seeking another reverse split and a 272,000-share equity plan increase is the next scheduled event.
How filings like this one have moved
In the 30 days to Oct 16, 2026, 36.9% of the 961 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VBIO was trading at $1.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3M. The 52-week trading range was $1.11 to $75.50. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.